
With the FDA expected to grant emergency-use approval for the Pfizer-BionTech COVID vaccine Thursday after releasing a preliminary assessment of the trial data that the panel will use to assess the drug earlier today, the agency has admitted Tuesday that two participants in the Phase 3 trials have died.
One of them was immunocompromised, according to the Jerusalem Post, citing data released earlier.















